摘要
目的评价豨莶通栓胶囊治疗急性缺血性脑卒中的有效性和安全性。方法前瞻性纳入2016年10月~2017年10月陆军总医院神经内科和空军总医院神经内科共同收治的急性缺血性脑卒中轻中度患者118例,随机分为试验组59例(口服豨莶通栓胶囊3粒/次,3次/d),对照组59例(安慰剂),2周为1个疗程。比较2组治疗前和治疗后14d美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)评分、治疗前和治疗后90d改良的Rankin量表评分及不良事件发生率。结果试验组治疗后14d NIHSS评分明显低于治疗前[(3.47±0.21)分vs(7.50±0.34)分,P<0.01],且明显低于对照组[(3.47±0.21)分vs(5.72±0.43)分,P<0.01],差异有统计学意义。试验组90d预后良好48例(81.4%),预后不良11例(18.6%),对照组90d预后良好39例(66.1%),预后不良20例(33.9%)。2组预后良好和预后不良比较,差异无统计学意义(P>0.05)。2组均无明显药物严重不良事件发生。结论豨莶通栓胶囊治疗急性缺血性脑卒中轻中度患者,可提高患者早期神经功能恢复,无明显不良反应。
Objective To assess the efficacy and safety of Xixiantongshuan capsule（XC）in treatment of acute ischemic stroke（AIS）.Methods One hundred and eighteen AIS patients from october 2016 to october 2017 were admitted to department of Neurology of Army General Hospital and Air Force General Hospital and randomly divided into XC group（n=59）and control group（n=59）.After the patients in XC group were treated with XC（3 XC once,3 times a day）and those in control group were treated with placebo with 14 days as a course of treatment,the national institute of health stroke scale（NIHSS）score,modified Rankin scale score and adverse reactions were compared between the two groups before treatment and 3 months after treatment.Results The NIHSS score was significantly lower in XC group after treatment than before treatment and in XC group than in control group（3.47±0.21 vs 7.50±0.34,P〈0.01;3.47±0.21 vs5.72±0.43,P〈0.01）.The outcome was good in 48 patients（81.4%）and poor in 11 patients（18.6%）of XC group and was good in 39 patients（66.1%）and poor in 20 patients（33.9%）of control group on day 90 after treatment.No significant difference was found in good and poor outcome between the two groups（P〉0.05）.No severe adverse reaction occurred in two groups.Conclusion XC can speed up the early recovery of nerve function in mild,moderate and severe AIS patients with no significant adverse reaction.
作者
夏振西
尹延伟
夏翠俏
张英谦
张微微
陈大伟
赵弘轶
黄勇华
Xia Zhenxi;Yin Yanwei;Xia Cuiqiao;Zhang Yingqian;Zhang Weiwei;Chen Dawei;Zhao Hongyi;Huang Yonghua(Department of Neurology,Chinese PLA Army General Hospital,Beijing 100700,China)
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2018年第10期1016-1018,共3页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词
卒中
豨莶草
中成药
预后
stroke
SIEGESBECKIA ORIENTALIS
CHINESE PATENT DRUGS
prognosis
